Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -24.19
- Piotroski Score 4.00
- Grade Hold
- Symbol (CARA)
- Company Cara Therapeutics, Inc.
- Price $0.29
- Changes Percentage (-5.98%)
- Change -$0.02
- Day Low $0.29
- Day High $0.32
- Year High $1.31
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $13.50
- High Stock Price Target $30.00
- Low Stock Price Target $1.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.26
- Trailing P/E Ratio -0.28
- Forward P/E Ratio -0.28
- P/E Growth -0.28
- Net Income $-118,513,000
Income Statement
Quarterly
Annual
Latest News of CARA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
ATP Tour Finals: Jannik Sinner, Alexander Zverev lead semifinals, Carlos Alcaraz out
The ATP Tour Finals in Turin have determined their semifinalists, with Jannik Sinner facing Casper Ruud and Alexander Zverev playing Taylor Fritz. The total prize money is $15....
By The New York Times | 3 days ago -
Carlos Alcaraz, tennis highlight reel, exits ATP Tour Finals knowing how to improve
Carlos Alcaraz, a rising tennis star, faces challenges at the end of the season due to health issues and exhaustion. Despite recent setbacks, he aims for consistency and remains a promising talent in ...
By The New York Times | 3 days ago -
Alcaraz aided by nasal band as he bounces back against Rublev in ATP Finals
Spaniard Carlos Alcaraz overcame respiratory issues to defeat Andrey Rublev in ATP Finals. The Billie Jean King Cup finals were delayed due to a weather warning in the Malaga region, with the opening ...
By The Guardian | 5 days ago
